Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 3
2006 2
2007 3
2008 2
2009 1
2010 1
2015 3
2016 1
2017 1
2018 2
2019 3
2020 2
2021 6
2022 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Targeting ALK Rearrangements in NSCLC: Current State of the Art.
Peng L, Zhu L, Sun Y, Stebbing J, Selvaggi G, Zhang Y, Yu Z. Peng L, et al. Among authors: selvaggi g. Front Oncol. 2022 Apr 6;12:863461. doi: 10.3389/fonc.2022.863461. eCollection 2022. Front Oncol. 2022. PMID: 35463328 Free PMC article. Review.
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL. Horn L, et al. Among authors: selvaggi g. JAMA Oncol. 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. JAMA Oncol. 2021. PMID: 34473194 Free PMC article. Clinical Trial.
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, Dakhil SR, Navarro A, Rodríguez-Cid J, Schenker M, Lee JS, Gutierrez V, Percent I, Morgensztern D, Barrios CH, Greillier L, Baka S, Patel M, Lin WH, Selvaggi G, Baudelet C, Baden J, Pandya D, Doshi P, Kim HR. Owonikoko TK, et al. Among authors: selvaggi g. J Clin Oncol. 2021 Apr 20;39(12):1349-1359. doi: 10.1200/JCO.20.02212. Epub 2021 Mar 8. J Clin Oncol. 2021. PMID: 33683919 Free PMC article. Clinical Trial.
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ, Barry E, Mossé YP, Ligas F, Bird N, de Rojas T, Zimmerman ZF, Wilner K, Woessmann W, Weiner S, Weigel B, Venkatramani R, Valteau D, Trahair T, Smith M, Singh S, Selvaggi G, Scobie N, Schleiermacher G, Richardson N, Park J, Nysom K, Norga K, Merino M, McDonough J, Matloub Y, Marshall LV, Lowe E, Lesa G, Irwin M, Karres D, Gajjar A, Doz F, Fox E, DuBois SG, Donoghue M, Casanova M, Caron H, Buenger V, Bradford D, Blanc P, Barone A, Reaman G, Vassal G. Pearson ADJ, et al. Among authors: selvaggi g. Eur J Cancer. 2021 Nov;157:198-213. doi: 10.1016/j.ejca.2021.08.022. Epub 2021 Sep 15. Eur J Cancer. 2021. PMID: 34536944 Free article. Review.
Emerging drugs for mesothelioma.
Scagliotti GV, Selvaggi G. Scagliotti GV, et al. Among authors: selvaggi g. Expert Opin Emerg Drugs. 2007 Mar;12(1):127-37. doi: 10.1517/14728214.12.1.127. Expert Opin Emerg Drugs. 2007. PMID: 17355218 Review.
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.
Zheng J, Wang T, Yang Y, Huang J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wang H, Cang S, Wu N, Song W, Liu X, Zhao S, Ding L, Selvaggi G, Wang Y, Xiao S, Wang Q, Shen Z, Zhou J, Zhou J, Zhang L. Zheng J, et al. Among authors: selvaggi g. Cancer Commun (Lond). 2024 Apr;44(4):455-468. doi: 10.1002/cac2.12524. Epub 2024 Feb 29. Cancer Commun (Lond). 2024. PMID: 38421881 Free PMC article. Clinical Trial.
Histologic subtype in NSCLC: does it matter?
Selvaggi G, Scagliotti GV. Selvaggi G, et al. Oncology (Williston Park). 2009 Nov 30;23(13):1133-40. Oncology (Williston Park). 2009. PMID: 20043461 Review.
Management of bone metastases in cancer: a review.
Selvaggi G, Scagliotti GV. Selvaggi G, et al. Crit Rev Oncol Hematol. 2005 Dec;56(3):365-78. doi: 10.1016/j.critrevonc.2005.03.011. Epub 2005 Jun 23. Crit Rev Oncol Hematol. 2005. PMID: 15978828 Review.
The oncolytic virus, pelareorep, as a novel anticancer agent: a review.
Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M. Chakrabarty R, et al. Among authors: selvaggi g. Invest New Drugs. 2015 Jun;33(3):761-74. doi: 10.1007/s10637-015-0216-8. Epub 2015 Feb 19. Invest New Drugs. 2015. PMID: 25693885 Review.
37 results